805 related articles for article (PubMed ID: 8644289)
1. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
2. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
3. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
4. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
5. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
6. Optimization of cyclosporine monotherapy--long-term graft function.
Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
[No Abstract] [Full Text] [Related]
7. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
8. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK
Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
[No Abstract] [Full Text] [Related]
9. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
[No Abstract] [Full Text] [Related]
10. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
[No Abstract] [Full Text] [Related]
11. Five-year experience with a triple drug protocol in renal transplantation.
Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
[No Abstract] [Full Text] [Related]
12. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival.
Howard RJ; Pfaff WW; Brunson ME; Ramos EL; Peterson JC; Croker BP; Scornik JC; Parris CJ; Fennell RS
Transplant Proc; 1993 Feb; 25(1 Pt 2):884. PubMed ID: 8442256
[No Abstract] [Full Text] [Related]
13. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
14. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
15. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
Niese D
Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531
[No Abstract] [Full Text] [Related]
16. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
17. High-dose cyclosporine A induction therapy in liver transplant recipients with normal postoperative renal function: a prospective study.
Cherqui D; Duvoux C; Salvat A; Lauzet JY; Metreau JM; Julien M; Fagniez PL; Dhumeaux D
Transplant Proc; 1995 Feb; 27(1):1134-5. PubMed ID: 7878824
[No Abstract] [Full Text] [Related]
18. Treatment of steroid resistant acute rejection after renal transplantation.
Oh CK; Kim YS; Kim MS; Kim SI; Park K
Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
[No Abstract] [Full Text] [Related]
19. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
[No Abstract] [Full Text] [Related]
20. Long-term results of OKT3-treated renal transplant recipients.
Tanabe K; Takahashi K; Sonda K; Tokumoto T; Koga S; Nakazawa H; Goya N; Yagisawa T; Fuchinoue S; Kawai T; Toma H; Ota K
Transplant Proc; 1996 Jun; 28(3):1350-1. PubMed ID: 8658689
[No Abstract] [Full Text] [Related]
[Next] [New Search]